Latest Off-label use Stories
EXTON, Pa., Jan. 11 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business and present a financial update during the 28th Annual J.P.
EXTON, Pa., Jan.
BOSTON, Oct. 16 /PRNewswire-USNewswire/ -- PHARMACIA & UPJOHN COMPANY, INC., a subsidiary of Pfizer Inc. ("Pfizer") today was sentenced today in federal court for a felony violation of the Food, Drug & Cosmetic Act, for misbranding the drug, Bextra, with the intent to defraud or mislead.
Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
The drug Instanyl helps treat breakthrough cancer pain, an Italian researcher said.
Pfizer to Pay $2.3 Billion for Fraudulent Marketing WASHINGTON, Sept. 2 /PRNewswire-USNewswire/ -- American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc.
PHILADELPHIA, Sept. 2 /PRNewswire/ -- Pfizer, Inc.
Includes Allegations of Illicitly Promoting Antibiotic As Clinically Superior When Its Own FDA-Approved Label Said Otherwise; First-Ever Qui Tam Whistleblower Settlement of Its Type PHILADELPHIA, Sept. 2 /PRNewswire-USNewswire/ -- Pfizer Inc.
The US Department of Justice said pharmaceutical giant Pfizer will pay a record $2.3 billion fine to settle fraudulent marketing of the painkiller Bextra.
- The governor of a province or people.